Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares
28 February 2023 - 9:19AM
Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global
biopharmaceutical company and leader in complement, today announced
the closing of its previously announced underwritten public
offering of common stock and pre-funded warrants, including the
exercise in full by the underwriters of their option to purchase an
additional 833,333 shares. The exercise of the option to purchase
additional shares increased the amount of gross proceeds, before
deducting underwriting discounts and commissions and offering
expenses payable by Apellis, to approximately $402.5 million.
The public offering consisted of 4,007,936 shares of common
stock at the public offering price of $63.00 per share, including
833,333 shares of common stock pursuant to the full exercise of the
underwriters’ option to purchase additional shares, and pre-funded
warrants to purchase 2,380,956 shares of common stock at the public
offering price of $62.9999 per pre-funded warrant.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and
Evercore Group L.L.C. acted as joint book-running managers for the
offering. Robert W. Baird & Co. Incorporated and Raymond James
& Associates, Inc., acted as co-managers for the offering.
The securities were offered by Apellis pursuant to an
automatically effective shelf registration statement that was filed
with the Securities and Exchange Commission (“SEC”) on February 22,
2023. This offering was made only by means of a prospectus and
prospectus supplement that form a part of the registration
statement. A final prospectus supplement relating to and describing
the terms of the offering has been filed with the SEC and may be
obtained for free by visiting the SEC’s website at www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus may also be obtained by contacting: J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, New York 11717, by telephone at
866-803-9204, or by email at prospectus-eq_fi@jpmchase.com; Goldman
Sachs & Co. LLC, Attention: Prospectus Department, 200 West
Street, New York, NY 10282, or by telephone at (866) 471-2526, or
by email at prospectus-ny@ny.email.gs.com; or Evercore Group
L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street,
35th Floor, New York, New York 10055, by telephone at (888)
474-0200, or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical
company that combines courageous science and compassion to develop
life-changing therapies for some of the most challenging diseases
patients face. We ushered in the first new class of complement
medicine in 15 years and now have two approved medicines targeting
C3. These include the first and only therapy for geographic
atrophy, a leading cause of blindness around the world. With nearly
a dozen clinical and pre-clinical programs underway, we believe we
have only begun to unlock the potential of targeting C3 across many
serious diseases.
Media Contact:Lissa
Pavlukmedia@apellis.com617.977.6764
Investor Contact: Meredith
Kaya meredith.kaya@apellis.com617.599.8178
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Apr 2023 to Apr 2024